| Dr Seth Michael Brown, MD | |
|
599 Farmington Ave, Farmington, CT 06032-2381 | |
| (860) 284-4950 | |
| Not Available |
| Full Name | Dr Seth Michael Brown |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 23 Years |
| Location | 599 Farmington Ave, Farmington, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679611701 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 044346 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Francis Hospital & Medical Center | Hartford, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Prohealth Physicians Pc | 1355246950 | 236 |
| University Of Connecticut Health Center | 3678472016 | 523 |
News Archive
Illumina today announced that on August 1, 2011, its Board of Directors authorized the Company to repurchase, on a discretionary basis, up to $100 million of its outstanding common shares in the open market or in privately negotiated transactions, subject to market conditions and other factors. The previous discretionary $100 million share repurchase program authorized in July 2010 was completed this week.
Many governors find themselves in an awkward spot since opposing the health care law is GOP orthodoxy. In the meantime, Iowa lawmakers approved a bill requiring licensure of advisers who help people navigate health insurance options.
International Isotopes Inc. announces completion of a private placement on October 29, 2010 that will immediately provide the company with approximately $5.8 million in cash to continue its efforts on the licensing and design of its planned environmentally friendly, green technology uranium de-conversion and fluorine extraction processing facility.
In a paper published in the December 2011 issue of Experimental Biology and Medicine, a team of scientists at the University of Illinois, Urbana-Champaign led by Rex Gaskins, PhD have demonstrated that both microbial and host inflammatory factors modulate sulfomucin production in a human cell line, LS174T, that models intestinal goblet cells.
AstraZeneca and MSD (Merck) announced today that the U.S. Food and Drug Administration (FDA) has granted acceptance to file status of its application for the MEK inhibitor selumetinib, for use in patients with plexiform neurofibromas, a common manifestation in the disease neurofibromatosis type one (NF1).
› Verified 8 days ago
| Entity Name | Prohealth Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720194053 PECOS PAC ID: 1355246950 Enrollment ID: O20031205000602 |
News Archive
Illumina today announced that on August 1, 2011, its Board of Directors authorized the Company to repurchase, on a discretionary basis, up to $100 million of its outstanding common shares in the open market or in privately negotiated transactions, subject to market conditions and other factors. The previous discretionary $100 million share repurchase program authorized in July 2010 was completed this week.
Many governors find themselves in an awkward spot since opposing the health care law is GOP orthodoxy. In the meantime, Iowa lawmakers approved a bill requiring licensure of advisers who help people navigate health insurance options.
International Isotopes Inc. announces completion of a private placement on October 29, 2010 that will immediately provide the company with approximately $5.8 million in cash to continue its efforts on the licensing and design of its planned environmentally friendly, green technology uranium de-conversion and fluorine extraction processing facility.
In a paper published in the December 2011 issue of Experimental Biology and Medicine, a team of scientists at the University of Illinois, Urbana-Champaign led by Rex Gaskins, PhD have demonstrated that both microbial and host inflammatory factors modulate sulfomucin production in a human cell line, LS174T, that models intestinal goblet cells.
AstraZeneca and MSD (Merck) announced today that the U.S. Food and Drug Administration (FDA) has granted acceptance to file status of its application for the MEK inhibitor selumetinib, for use in patients with plexiform neurofibromas, a common manifestation in the disease neurofibromatosis type one (NF1).
› Verified 8 days ago
| Entity Name | University Of Connecticut Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720083769 PECOS PAC ID: 3678472016 Enrollment ID: O20040106000105 |
News Archive
Illumina today announced that on August 1, 2011, its Board of Directors authorized the Company to repurchase, on a discretionary basis, up to $100 million of its outstanding common shares in the open market or in privately negotiated transactions, subject to market conditions and other factors. The previous discretionary $100 million share repurchase program authorized in July 2010 was completed this week.
Many governors find themselves in an awkward spot since opposing the health care law is GOP orthodoxy. In the meantime, Iowa lawmakers approved a bill requiring licensure of advisers who help people navigate health insurance options.
International Isotopes Inc. announces completion of a private placement on October 29, 2010 that will immediately provide the company with approximately $5.8 million in cash to continue its efforts on the licensing and design of its planned environmentally friendly, green technology uranium de-conversion and fluorine extraction processing facility.
In a paper published in the December 2011 issue of Experimental Biology and Medicine, a team of scientists at the University of Illinois, Urbana-Champaign led by Rex Gaskins, PhD have demonstrated that both microbial and host inflammatory factors modulate sulfomucin production in a human cell line, LS174T, that models intestinal goblet cells.
AstraZeneca and MSD (Merck) announced today that the U.S. Food and Drug Administration (FDA) has granted acceptance to file status of its application for the MEK inhibitor selumetinib, for use in patients with plexiform neurofibromas, a common manifestation in the disease neurofibromatosis type one (NF1).
› Verified 8 days ago
| Entity Name | Ear Nose & Throat Institute Of Connecticut Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316724891 PECOS PAC ID: 4284078296 Enrollment ID: O20240219000430 |
News Archive
Illumina today announced that on August 1, 2011, its Board of Directors authorized the Company to repurchase, on a discretionary basis, up to $100 million of its outstanding common shares in the open market or in privately negotiated transactions, subject to market conditions and other factors. The previous discretionary $100 million share repurchase program authorized in July 2010 was completed this week.
Many governors find themselves in an awkward spot since opposing the health care law is GOP orthodoxy. In the meantime, Iowa lawmakers approved a bill requiring licensure of advisers who help people navigate health insurance options.
International Isotopes Inc. announces completion of a private placement on October 29, 2010 that will immediately provide the company with approximately $5.8 million in cash to continue its efforts on the licensing and design of its planned environmentally friendly, green technology uranium de-conversion and fluorine extraction processing facility.
In a paper published in the December 2011 issue of Experimental Biology and Medicine, a team of scientists at the University of Illinois, Urbana-Champaign led by Rex Gaskins, PhD have demonstrated that both microbial and host inflammatory factors modulate sulfomucin production in a human cell line, LS174T, that models intestinal goblet cells.
AstraZeneca and MSD (Merck) announced today that the U.S. Food and Drug Administration (FDA) has granted acceptance to file status of its application for the MEK inhibitor selumetinib, for use in patients with plexiform neurofibromas, a common manifestation in the disease neurofibromatosis type one (NF1).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Seth Michael Brown, MD 599 Farmington Ave, Farmington, CT 06032-2381 Ph: (860) 284-5266 | Dr Seth Michael Brown, MD 599 Farmington Ave, Farmington, CT 06032-2381 Ph: (860) 284-4950 |
News Archive
Illumina today announced that on August 1, 2011, its Board of Directors authorized the Company to repurchase, on a discretionary basis, up to $100 million of its outstanding common shares in the open market or in privately negotiated transactions, subject to market conditions and other factors. The previous discretionary $100 million share repurchase program authorized in July 2010 was completed this week.
Many governors find themselves in an awkward spot since opposing the health care law is GOP orthodoxy. In the meantime, Iowa lawmakers approved a bill requiring licensure of advisers who help people navigate health insurance options.
International Isotopes Inc. announces completion of a private placement on October 29, 2010 that will immediately provide the company with approximately $5.8 million in cash to continue its efforts on the licensing and design of its planned environmentally friendly, green technology uranium de-conversion and fluorine extraction processing facility.
In a paper published in the December 2011 issue of Experimental Biology and Medicine, a team of scientists at the University of Illinois, Urbana-Champaign led by Rex Gaskins, PhD have demonstrated that both microbial and host inflammatory factors modulate sulfomucin production in a human cell line, LS174T, that models intestinal goblet cells.
AstraZeneca and MSD (Merck) announced today that the U.S. Food and Drug Administration (FDA) has granted acceptance to file status of its application for the MEK inhibitor selumetinib, for use in patients with plexiform neurofibromas, a common manifestation in the disease neurofibromatosis type one (NF1).
› Verified 8 days ago
Nicholas Stephen Karter, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 499 Farmington Ave, Farmington, CT 06032 Phone: 860-676-2472 Fax: 860-678-9119 | |
Dr. Daniel Stewart Roberts, M.D Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: Uconn Medical Group, 263 Farmington Avenue, Farmington, CT 06030 Phone: 860-679-2804 Fax: 860-679-1848 | |
Kimberley D Rutherford, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 599 Farmington Ave Ste 102, Farmington, CT 06032 Phone: 860-284-4950 Fax: 860-284-4951 | |
Hailun Wang, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 21 South Rd Ste 112, Farmington, CT 06032 Phone: 860-284-4950 Fax: 860-284-4951 | |
Belachew Tessema, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 21 South Rd, Farmington, CT 06032 Phone: 860-284-4950 | |
Kourosh Parham, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 263 Farmington Ave, Farmington, CT 06030 Phone: 860-679-2804 Fax: 860-679-1848 | |
Dr. Brook M. Seeley, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 499 Farmington Ave., Suite 210, Farmington, CT 06030 Phone: 860-676-2472 Fax: 860-678-9119 |